JPWO2022258974A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022258974A5 JPWO2022258974A5 JP2023575729A JP2023575729A JPWO2022258974A5 JP WO2022258974 A5 JPWO2022258974 A5 JP WO2022258974A5 JP 2023575729 A JP2023575729 A JP 2023575729A JP 2023575729 A JP2023575729 A JP 2023575729A JP WO2022258974 A5 JPWO2022258974 A5 JP WO2022258974A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently selected
- groups
- optionally substituted
- pharma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2108334.0A GB202108334D0 (en) | 2021-06-10 | 2021-06-10 | Compounds |
| GB2108334.0 | 2021-06-10 | ||
| GB2118633.3 | 2021-12-21 | ||
| GB202118633 | 2021-12-21 | ||
| PCT/GB2022/051446 WO2022258974A1 (en) | 2021-06-10 | 2022-06-09 | Quinazoline derivatives useful as ras inhibitiors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024520791A JP2024520791A (ja) | 2024-05-24 |
| JP2024520791A5 JP2024520791A5 (https=) | 2025-06-13 |
| JPWO2022258974A5 true JPWO2022258974A5 (https=) | 2025-06-13 |
Family
ID=82156695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023575729A Pending JP2024520791A (ja) | 2021-06-10 | 2022-06-09 | 化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240287078A1 (https=) |
| EP (1) | EP4352061A1 (https=) |
| JP (1) | JP2024520791A (https=) |
| KR (1) | KR20240021197A (https=) |
| AU (1) | AU2022288151A1 (https=) |
| BR (1) | BR112023025869A2 (https=) |
| CA (1) | CA3218237A1 (https=) |
| IL (1) | IL308813A (https=) |
| MX (1) | MX2023014786A (https=) |
| WO (1) | WO2022258974A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12479834B2 (en) | 2019-11-29 | 2025-11-25 | Taiho Pharmaceutical Co., Ltd. | Phenol compound or salt thereof |
| CN116368130A (zh) | 2020-08-28 | 2023-06-30 | 金橘生物科技公司 | 杂环化合物及其用途 |
| WO2022056307A1 (en) | 2020-09-11 | 2022-03-17 | Mirati Therapeutics, Inc. | Crystalline forms of a kras g12c inhibitor |
| WO2022132200A1 (en) | 2020-12-15 | 2022-06-23 | Mirati Therapeutics, Inc. | Azaquinazoline pan-kras inhibitors |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| TW202328124A (zh) * | 2021-08-18 | 2023-07-16 | 大陸商北京加科思新藥研發有限公司 | 1,4-氧雜氮雜環庚烷衍生物及其用途 |
| CN118556063A (zh) * | 2022-01-21 | 2024-08-27 | 上海湃隆生物科技有限公司 | 杂环类化合物、药物组合物及其应用 |
| IL314486A (en) * | 2022-02-03 | 2024-09-01 | Mirati Therapeutics Inc | Quinazoline compounds inhibit PAN-KRAS |
| EP4479398A1 (en) * | 2022-02-16 | 2024-12-25 | Amgen Inc. | Quinazoline compounds and use thereof as inhibtors of mutant kras proteins |
| AU2023222076A1 (en) * | 2022-02-16 | 2024-08-15 | Amgen Inc. | Quinazoline compounds and use thereof as inhibtors of mutant kras proteins |
| WO2024008068A1 (en) * | 2022-07-04 | 2024-01-11 | Jacobio Pharmaceuticals Co., Ltd. | K-ras mutant protein inhibitors |
| CN117659050A (zh) * | 2022-09-08 | 2024-03-08 | 深圳福沃药业有限公司 | 用于治疗癌症的kras突变抑制剂的喹唑啉杂环类衍生物 |
| CN120077051A (zh) * | 2022-10-21 | 2025-05-30 | 苏州亚盛药业有限公司 | Kras抑制剂 |
| WO2024112654A1 (en) | 2022-11-21 | 2024-05-30 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| KR20260015208A (ko) | 2023-05-12 | 2026-02-02 | 재즈 파마슈티칼즈 아일랜드 리미티드 | 암 치료에 유용한 g12d 돌연변이체 kras의 조절제로서 피라졸로[4,3-f]퀴나졸린 유도체 |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| AU2024323424A1 (en) | 2023-08-17 | 2026-03-05 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025085748A1 (en) | 2023-10-20 | 2025-04-24 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| WO2025163494A1 (en) | 2024-01-29 | 2025-08-07 | Jazz Pharmaceuticals Ireland Ltd. | Condensed azines for the treatment of cancer |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025235740A1 (en) * | 2024-05-08 | 2025-11-13 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017172979A1 (en) * | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| JOP20190186A1 (ar) * | 2017-02-02 | 2019-08-01 | Astellas Pharma Inc | مركب كينازولين |
| AU2018271990A1 (en) * | 2017-05-25 | 2019-12-12 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| WO2020146613A1 (en) * | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| WO2021041671A1 (en) * | 2019-08-29 | 2021-03-04 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| WO2022002102A1 (en) * | 2020-06-30 | 2022-01-06 | InventisBio Co., Ltd. | Quinazoline compounds, preparation methods and uses thereof |
| CN116368130A (zh) * | 2020-08-28 | 2023-06-30 | 金橘生物科技公司 | 杂环化合物及其用途 |
| US20230081426A1 (en) * | 2020-09-18 | 2023-03-16 | Plexxikon Inc. | Compounds and methods for kras modulation and indications therefor |
| US20230365563A1 (en) * | 2020-09-30 | 2023-11-16 | Shanghai Pharmaceuticals Holding Co., Ltd. | Quinazoline compound and application thereof |
| WO2022098625A1 (en) * | 2020-11-03 | 2022-05-12 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| US20240059710A1 (en) * | 2020-11-20 | 2024-02-22 | Jacobio Pharmaceuticals Co., Ltd. | KRAS G12D Inhibitors |
| US20240109893A1 (en) * | 2020-12-22 | 2024-04-04 | Shanghai Kechow Pharma, Inc. | Preparation and application method of heterocyclic compounds as kras inhibitor |
| CN113999226B (zh) * | 2020-12-22 | 2023-01-06 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物的制备及其应用方法 |
| US20240140957A1 (en) * | 2021-01-08 | 2024-05-02 | Beigene Switzerland Gmbh | Bridged compounds as kras g12d inhibitor and degrader and the use thereof |
| CN114031562A (zh) * | 2021-10-31 | 2022-02-11 | 南京碳硅人工智能生物医药技术研究院有限公司 | 一种具有抗肿瘤的吡啶衍生物的工艺优化 |
-
2022
- 2022-06-09 JP JP2023575729A patent/JP2024520791A/ja active Pending
- 2022-06-09 EP EP22732623.8A patent/EP4352061A1/en active Pending
- 2022-06-09 AU AU2022288151A patent/AU2022288151A1/en active Pending
- 2022-06-09 CA CA3218237A patent/CA3218237A1/en active Pending
- 2022-06-09 BR BR112023025869A patent/BR112023025869A2/pt unknown
- 2022-06-09 MX MX2023014786A patent/MX2023014786A/es unknown
- 2022-06-09 IL IL308813A patent/IL308813A/en unknown
- 2022-06-09 WO PCT/GB2022/051446 patent/WO2022258974A1/en not_active Ceased
- 2022-06-09 KR KR1020237044900A patent/KR20240021197A/ko active Pending
- 2022-06-09 US US18/565,009 patent/US20240287078A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022258974A5 (https=) | ||
| JPWO2022248885A5 (https=) | ||
| JP2022177278A (ja) | がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物 | |
| ES3009132T3 (en) | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one derivatives, salts thereof and their use in therapy | |
| ES2281007T3 (es) | Derivados de quinazolina. | |
| KR102430942B1 (ko) | 우레아 화합물, 이의 제조 방법 및 이의 의학적 용도 | |
| JPWO2020106640A5 (https=) | ||
| RU2010131833A (ru) | Способы получения производных хиназолинона | |
| JP2018511631A5 (https=) | ||
| JP2021510376A5 (https=) | ||
| RU2009146832A (ru) | Производные хиназолиноксима в качестве ингибиторов hsp90 | |
| BR112018012914B1 (pt) | Composto, uso de um composto e composição farmacêutica | |
| KR20070050478A (ko) | 세포 증식과 관련된 질환 치료용 배합물 | |
| AU2015213679A1 (en) | Pharmaceutical compounds | |
| JP2005538100A5 (https=) | ||
| KR20220123335A (ko) | 7-벤질-10-(2-메틸벤질)-2,6,7,8,9,10-헥사하이드로이미다조[1,2-a]피리도[4,3-d]피리미딘-5(3h)-온과의 조합 치료요법 | |
| JP2004509111A (ja) | Ｎ−フェニル−２−ピリミジン−アミン誘導体 | |
| BG104960A (en) | Bicyclic pirimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | |
| RU2007123360A (ru) | Пирролопиразины и пиразолопиразины, полезные в качестве ингибиторов протеинкиназ | |
| JP2008528469A5 (https=) | ||
| RU2011119478A (ru) | Соединения и способы применения | |
| JP2021519786A5 (https=) | ||
| BR112016011072B1 (pt) | Composto 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9- hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h) -ona e composição farmacêutica contendo o referido composto | |
| JP2025061387A (ja) | 複素環式タンパク質キナーゼ阻害剤を含む製剤 | |
| WO2016089208A2 (en) | Sulfonamide, sulfamate and sulfamide derivatives of anti-cancer agents |